Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Materials Science, Multidisciplinary
Qingxin Mu, Guanyou Lin, Mike Jeon, Hui Wang, Fei-Chien Chang, Richard A. Revia, John Yu, Miqin Zhang
Summary: This study presents a multifunctional nanoparticle formulation targeting TNBC cells and dendritic cells, inducing tumor apoptosis through multiple mechanisms and significantly inhibiting tumor growth and metastasis while extending survival in a drug-resistant mouse model of TNBC. The promising platform may substantially improve therapeutic efficacy for treating metastatic TNBC.
Review
Pharmacology & Pharmacy
Yifeng Cao, Chuyang Chen, Yi Tao, Weifeng Lin, Ping Wang
Summary: Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, leading to increased mortality of patients due to accelerated aggressiveness and terrible metastasis. Hindered by the negative expression of certain receptors, targeted therapy has been challenging, but the higher immune response in TNBC compared to other breast cancer types makes it suitable for immunotherapy.
Article
Engineering, Biomedical
Zhenghu Chen, Zihua Zeng, Quanyuan Wan, Xiaohui Liu, Jianjun Qi, Youli Zu
Summary: This study demonstrates a novel immunotherapeutic approach for targeting triple-negative breast cancer (TNBC) using aptamer-engineered NK cells. The synthetic aptamer probes selectively target TNBC cell lines and trigger apoptosis and death of cultured TNBC cells. Systemic administration of aptamer-engineered NK cells inhibits lung metastasis in mice harboring TNBC xenografts.
Review
Oncology
Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov, Yongheng Chen
Summary: Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Summary: TNBC, characterized by absence of ER, PR, and HER2 expression, is a highly aggressive subtype of breast cancer. Conventional chemotherapy remains the main treatment, but the lack of targeted therapies has led to exploration of PARP inhibitors and immune checkpoint inhibitors as potential options. Other agents targeting various pathways are also under investigation.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Abygail G. Chapdelaine, Gongqin Sun
Summary: Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. Accumulating evidence supports TNBCs as multi-driver cancers, and a strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed.
Article
Biochemistry & Molecular Biology
Alyssa Vito, Stephanie Rathmann, Natalie Mercanti, Nader El-Sayes, Karen Mossman, John Valliant
Summary: The study investigated the combination of radionuclide therapy and immunotherapy for breast cancer, finding that neither monotherapy improved therapeutic outcomes, but the combination significantly extended overall survival and reduced necrotic tissue within the tumor, as well as suppressed inflammatory cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Nanoscience & Nanotechnology
Xiaoxi Wang, Xueqin Zhu, Bingyu Li, Xiuyu Wei, Yalan Chen, Yun Zhang, Yan Wang, Wenyan Zhang, Sijia Liu, Zimai Liu, Wenjie Zhai, Pingping Zhu, Yanfeng Gao, Zhenzhen Chen
Summary: An intelligent bionic nanoplatform combining targeted therapy with immunotherapy was developed to treat triple-negative breast cancer. In vitro and in vivo experiments demonstrated that this nanoplatform effectively inhibited the growth and metastasis of breast cancer and triggered an anti-tumor immune response.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Oncology
Xu Cao, Bolei Li, Jing Chen, Jessica Dang, Siqi Chen, E. Gulsen Gunes, Bo Xu, Lei Tian, Sabina Muend, Mustafa Raoof, Christiane Querfeld, Jianhua Yu, Steven T. Rosen, Yingyu Wang, Mingye Feng
Summary: The study found that blocking CD47 and using cabazitaxel can significantly promote the programmed cell removal of TNBC cells, inhibiting tumor development and metastasis, providing a promising new strategy for TNBC treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Mahak Fatima, Afsana Sheikh, Mohammed A. S. Abourehab, Prashant Kesharwani
Summary: Triple-negative breast cancer is a destructive disease with poor prognosis and low survival rate. Current therapies have limitations, and thus, new approaches using polymeric nanocarriers are important for effective treatment of TNBC.
Review
Medicine, General & Internal
Hyeryeon Choi, Kwangsoon Kim
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Current treatment options are limited and variable response to chemotherapy exists due to disease heterogeneity. This review discusses FDA-approved targeted therapies for TNBC, as well as novel theranostic approaches using nanocarriers. These approaches aim to improve diagnosis and treatment of TNBC by enabling targeted drug delivery and visualization of the lesion.
Article
Oncology
Ghazal Nabil, Rami Alzhrani, Hashem O. Alsaab, Mohammed Atef, Samaresh Sau, Arun K. Iyer, Hossny El Banna
Summary: Triple-negative breast cancer (TNBC) is a challenging and aggressive tumor with limited therapeutic options. Combination therapies, such as using apoptosis inducers and JAK/STAT3 inhibitors, have shown improvement in TNBC cell killing activity. CD44 targeted polymeric nanoparticles and Hyaluronic acid-tagged nanoparticles have enhanced drug activity and tumor accumulation, leading to improved therapeutic efficacy for TNBC treatment.
Review
Biochemistry & Molecular Biology
Cristina J. Dias, Luisa Helguero, Maria Amparo F. Faustino
Summary: This article reviews the latest developments in targeted therapy for triple-negative breast cancer using chlorin-based photoactive molecules. Photodynamic therapy, whether used alone or in combination with other therapies such as chemotherapy or photothermal therapy, has the potential to be a safe and promising approach against TNBC.
Article
Chemistry, Multidisciplinary
Zitong Zhao, Lei Fang, Ping Xiao, Xiangshi Sun, Lei Zhou, Xiaochen Liu, Jue Wang, Guanru Wang, Haiqiang Cao, Pengcheng Zhang, Yanyan Jiang, Dangge Wang, Yaping Li
Summary: In this study, walking dead TNBC cells were developed by conjugating anti-PD-1 and doxorubicin-loaded liposomes onto cell corpses for temporal chemo-immunotherapy against lung metastasis. The walking dead TNBC cells improved drug accumulation and local retention in the lungs, reprogrammed the lung microenvironment, and prolonged overall survival in mice with lung metastasis.
ADVANCED MATERIALS
(2022)
Article
Oncology
Yiqun Li, Qiao Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Ye Zhang, Dainan Zhang, Shanshan Chen, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: The study examined the incidence, risk factors, and survival of brain metastases at the initial diagnosis of metastatic breast cancer in China, revealing that patients with HER2-positive and TNBC subtypes have a higher risk of developing brain metastases at the initial diagnosis of MBC.
Article
Oncology
Shaoyan Lin, Hongnan Mo, Yiqun Li, Xiuwen Guan, Yimeng Chen, Zijing Wang, Peng Yuan, Jiayu Wang, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Shanshan Chen, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: This study conducted analyses on BCLM patients in the Han population and found that HR-/HER2+ and HR+/HER2+ subtypes, as well as patients with de novo stage IV breast cancer, had a higher risk of liver metastases, while patients with lung metastases had a lower risk. The median overall survival of BCLM patients was 31.4 months, with patients of HR+/HER2- subtype having the longest survival time of 38.2 months.
FRONTIERS IN ONCOLOGY
(2021)
Meeting Abstract
Oncology
Jiayu Wang, Binghe Xu, Tao Sun, Quchang Ouyang, Yiqun Han, Qing Li, Pin Zhang, Fei Ma, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Bo Lan, Hongnan Mo, Jiani Wang, Yiqun Li
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yiqun Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: The study aimed to observe whether guideline non-adherence in initial palliative treatment choices for premenopausal HR+ HER2- MBC patients in China leads to worse clinical outcomes. The results showed that in real world, a high percentage of premenopausal patients with HR+ HER2- disease received chemotherapy as initial palliative treatment in China, but this was not associated with worsened survival. Further studies with larger sample size across China are needed to explore the relationship between this guideline non-adherence and clinical outcomes.
Article
Oncology
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu, Fei Ma, Zemin Zhang, Zhihua Liu
Summary: The study indicates that high levels of baseline CXCL13(+) T cells are associated with effective responses to combination therapy in triple-negative breast cancer patients. These cells increase following combination therapy but decrease after monotherapy, highlighting their importance in predicting treatment outcomes.
Article
Oncology
Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: The study found that HER2-low breast cancer presents distinct clinical features and survival outcomes compared to HER2-negative breast cancer, particularly in the HR-positive subgroup. This type of breast cancer may have a more complex molecular landscape, and further research on more precise diagnostic algorithms could lead to new therapeutic targets.
FRONTIERS IN ONCOLOGY
(2022)
Meeting Abstract
Oncology
Yiqun Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Article
Oncology
Lin Wang, Yanrong Zhu, Bo Zhang, Xi Wang, Hongnan Mo, Yuchen Jiao, Jiachen Xu, Jing Huang
Summary: This study suggests that NLR and HLA-I genotyping may have predictive and prognostic value in patients with advanced ESCC receiving camrelizumab, and the combination of biomarkers may help to identify more patient benefit from immunotherapy.
Article
Oncology
Yantong Zhou, Peng Nan, Chunxiao Li, Hongnan Mo, Ying Zhang, Haijuan Wang, Dongkui Xu, Fei Ma, Haili Qian
Summary: Upregulation of MTA1 in colorectal cancer drives an immunosuppressive tumor microenvironment by decreasing tumor-associated macrophages and inducing their phenotypic change, which weakens the cytotoxic effect of CD8(+) T cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hongnan Mo, Xuefeng Liu, Yu Xue, Hongyan Chen, Shichao Guo, Zhangfu Li, Shuang Wang, Caiming Li, Jiashu Han, Ming Fu, Yongmei Song, Dan Li, Fei Ma
Summary: The innate resistance mechanism to CDK4/6 inhibitors is S6K1 amplification, which accounts for a certain proportion in breast cancer patients. Patients with S6K1 amplification have poor response to CDK4/6 inhibitors and may benefit from the combination of CDK4/6 and S6K1 antagonists.
Article
Medicine, General & Internal
Hongnan Mo, Xiaoyan Yan, Fang Zhao, Yuee Teng, Xiaoying Sun, Zheng Lv, Mengru Cao, Jiuda Zhao, Guohong Song, Bo Pan, Huihui Li, Jingtong Zhai, Binghe Xu, Fei Ma
Summary: This study aimed to compare the symptom spectrum of chemotherapy-induced peripheral neuropathy (CIPN) associated with nab-paclitaxel, paclitaxel, and docetaxel treatments among patients with breast cancer. The study found that paclitaxel and docetaxel were associated with a more severe symptom spectrum of CIPN compared to nab-paclitaxel. Additionally, patients receiving paclitaxel and docetaxel reported motor symptoms earlier than sensory symptoms, and had lower discomfort in both sensory and motor aspects.
Article
Medicine, General & Internal
Hongnan Mo, Fei Ma, Qing Li, Pin Zhang, Peng Yuan, Jiayu Wang, Yang Luo, Ruigang Cai, Qiao Li, Binghe Xu
Summary: This study aimed to reveal the treatment patterns and clinical outcomes of different palbociclib-based regimens in Han patients with ER+ metastatic breast cancer. The results showed that the median PFS was similar among different palbociclib-combined groups. Patients who had received previous everolimus treatment had worse PFS and lower disease control rate than those who were everolimus-naive, but after propensity score matching, the PFS was similar between the two groups.
CHINESE MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Zongbi Yi, Fei Ma, Guohua Rong, Binliang Liu, Yanfang Guan, Jin Li, Xiaoying Sun, Wenna Wang, Xiuwen Guan, Hongnan Mo, Jiani Wang, Haili Qian, Binghe Xu
Summary: The study discovered that mTBI in ctDNA is a potential biomarker for therapeutic response and prognosis in metastatic breast cancer patients. Patients with high mTBI values had shorter overall survival, while those with decreased mTBI values after treatment had longer progression-free and overall survival.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Yimeng Chen, Yin Guan, Jiayu Wang, Fei Ma, Yang Luo, Shanshan Chen, Pin Zhang, Qing Li, Ruigang Cai, Qiao Li, Hongnan Mo, Ying Fan, Weihong Zhao, Binghe Xu
Summary: In this study, capecitabine-based chemotherapy showed better efficacy in terms of objective response rate and overall survival compared to platinum-based chemotherapy for TNBC patients with liver metastasis in the first-line treatment. Therefore, further large-scale studies are warranted to confirm these findings.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
